Diatrizoic Acid

Summary

Diatrizoic Acid (CHEMBL1201220) is an approved small-molecule radioopaque medium (ATC V08AA01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AA01
• Clinical trials: 1
• Chemistry: 613.91 Da · C11H9I3N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201220
Name	Diatrizoic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2140
ChEBI	CHEBI:53691
ATC	V08AA01
Molecular formula	C11H9I3N2O4
Molecular weight	613.91
InChIKey	YVPYQUNUQOZFHG-UHFFFAOYSA-N

SMILES: CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I

IUPAC name: 3,5-diacetamido-2,4,6-triiodobenzoic acid

ChEBI definition: A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.

Pharmacological roles (ChEBI): radioopaque medium.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Acidum amidotrizoicum, anhydrous, Amidotrizoic acid, Diatrizoate, Diatrizoic acid, NSC-262168, Odiston, Urografin acid, Urogranoic acid, Urotrast, Diatrizoic Acid, DIATRIZOIC ACID

Parent form; salt/anhydrous children: CHEMBL1200581, CHEMBL1200839, CHEMBL1534228, CHEMBL2106216, CHEMBL3188504

Patent coverage: 9,818 distinct patent families (25,497 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02542046	Not specified	COMPLETED	Uniformity of Oral Contrast Material in the Bowel

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).